SEC Form 4 · accession 0001179110-15-008668
ABIOMED INC · ABMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael R Minogue
Officer — President, CEO, Chairman · Director
Period of report
May 26, 2015
Accepted (ET)
May 28, 2015 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000815094
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock $.01 par valueF6,F7 | May 26, 2015 | S | 12,569 | $60.0309 | D | 312,220 | D | |
| Common Stock $.01 par valueF6,F8 | May 26, 2015 | S | 1,824 | $60.8798 | D | 310,396 | D | |
| Common Stock $.01 par valueF6,F9 | May 26, 2015 | S | 1,596 | $61.8675 | D | 308,800 | D | |
| Common Stock $.01 par valueF10 | May 14, 2015 | G | 20,660 | $0.00 | D | 288,140 | D | |
| Common Stock $.01 par valueF10 | May 26, 2015 | G | 33,244 | $0.00 | D | 254,896 | D | |
| Common Stock $.01 par valueF10 | May 14, 2015 | G | 20,660 | $0.00 | A | 20,660 | I | By Trust |
| Common Stock $.01 par valueF10 | May 26, 2015 | G | 33,244 | $0.00 | A | 53,904 | I | By Trust |
| Common Stock $.01 par valueF11 | May 27, 2015 | G | 33,000 | $0.00 | D | 20,904 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $13.57 | holding | — | — | — | Jun 1, 2007 | Jun 1, 2016 | Common Stock | 0 | 82,000 | D |
| Stock Option (right to buy)F1,F2 | $13.80 | holding | — | — | — | May 23, 2009 | May 23, 2018 | Common Stock | 0 | 28,333 | D |
| Stock Option (right to buy)F3,F4 | $18.63 | holding | — | — | — | Jun 15, 2009 | Aug 13, 2018 | Common Stock | 0 | 76,875 | D |
| Stock Option (right to buy)F3,F2 | $5.86 | holding | — | — | — | May 28, 2010 | May 28, 2019 | Common Stock | 0 | 146,800 | D |
| Stock Option (right to buy)F3,F2 | $5.86 | holding | — | — | — | May 28, 2010 | May 28, 2019 | Common Stock | 0 | 56,700 | D |
| Stock Option (right to buy)F3,F2 | $10.03 | holding | — | — | — | Jun 3, 2011 | Jun 3, 2020 | Common Stock | 0 | 105,000 | D |
| Stock Option (Right to Buy)F3,F2 | $22.44 | holding | — | — | — | May 22, 2013 | May 22, 2022 | Common Stock | 0 | 50,000 | D |
| Stock Option (Right to Buy)F3,F2 | $23.15 | holding | — | — | — | May 14, 2014 | May 14, 2024 | Common stock | 0 | 21,250 | D |
| Stock Option (right to buy)F3,F5 | $21.55 | holding | — | — | — | May 14, 2015 | May 14, 2024 | Common Stock | 0 | 85,000 | D |
| Stock Option (right to buy)F3,F5 | $66.25 | holding | — | — | — | May 13, 2016 | May 13, 2025 | Common Stock | 0 | 35,000 | D |
Explanation of responses
- F1Grant to reporting person of option to buy shares of Common Stock under the ABIOMED, Inc. 2000 Stock Incentive Plan.
- F10This transaction represents the transfer of common stock by bona fide gift from the reporting person to the Renee D. Minogue Revocable Trust, Renee D. Minogue, trustee DTD 12/29/2005.
- F11This transaction represents the transfer of common stock by bona fide gift from the Renee Minogue Revocable Trust, Renee D. Minogue, trustee DTD 12/29/2005 to a charitable foundation.
- F2These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- F3Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- F4These options become exercisable based on the achievement of certain performance milestones.
- F5These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- F6Sale of common stock pursuant to reporting owner's 10b5-1 plan, solely for payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards.
- F7This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $59.5200 and $60.5100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F8This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $60.5400 and $61.5000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F9This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $61.6000 and $62.1400. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.